Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis-Reference-Cited by-同舟云学术

Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis

Published:2022-10-22 Issue:6 Volume:17 Page:643-653
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Niizeki Takashi,Tokunaga Takayuki,Takami Yuko,Wada Yoshiyuki,Harada Masaru,Shibata Michihiko,Nakao Kazuhiko,Sasaki Ryu,Hirai Fumihito,Shakado Satoshi,Yoshizumi Tomoharu,Itoh Shinji,Yatsuhashi Hiroshi,Bekki Shigemune,Ido Akio,Mawatari Seiichi,Honda Koichi,Sugimoto Rie,Senju Takeshi,Takahashi Hirokazu,Kuwashiro Takuya,Maeshiro Tatsuji,Nakamuta Makoto,Aratake Yoshifusa,Yamashita Tsutomu,Otsuka Yuichiro,Matsumoto Shuichi,Sohda Tetsuro,Shimose Shigeo^ORCID,Murotani Kenta,Tanaka Yasuhito

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-022-00921-x.pdf

Reference26 articles.

1. Kudo M. Systemic therapy for hepatocellular carcinoma: latest advances. Cancers (Basel). 2018;10(11):412.

2. Kudo M. Management of hepatocellular carcinoma in Japan: current trends. Liver Cancer. 2020;9(1):1–5.

3. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905.

4. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73.

5. Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful radical surgery for lymph node metastasis in a patient with hepatocellular carcinoma following atezolizumab plus bevacizumab combination therapy: a case report and literature review;Clinical Journal of Gastroenterology;2024-08-20

2. Heterogeneity in adverse events related to Atezolizumab-Bevacizumab for hepatocellular carcinoma reported in real-life studies;JHEP Reports;2024-08

3. Improved survival outcome of curative liver resection for Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma in the era of tyrosine kinase inhibitors;Hepatology Research;2024-07-26

4. Is atezolizumab plus bevacizumab as first-line therapy for unresectable hepatocellular carcinoma superior to lenvatinib? a systematic review and meta‑analysis;European Journal of Clinical Pharmacology;2024-06-22

5. Robot-assisted extended rectal anterior resection for peritoneal dissemination of hepatocellular carcinoma invading rectum after atezolizumab plus bevacizumab combined therapy;International Cancer Conference Journal;2024-06-05